FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1643-1644 May 24, 2001 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: With reference to the review article by Busse and Lemanske on asthma (Feb. 1 issue),¹ we would like to raise the following points. Figure 4 fails to make it clear that several serious diseases, including type 1 diabetes,² are mediated by a type 1 helper-T-cell (Th1) response; for this reason, any immunotherapy aimed at manipulating the helper-T-cell response in favor of a Th1 response may have unwanted effects, such as the development of Th1-mediated diseases. Type 1 diabetes, like atopy, commonly presents early in life, is also rising in incidence in Europe, and is most common in . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Lundy, S. K., Berlin, A. A., Lukacs, N. W. (2003). Interleukin-12-Independent Down-Modulation of Cockroach Antigen-Induced Asthma in Mice by Intranasal Exposure to Bacterial Lipopolysaccharide. Am. J. Pathol. 163: 1961-1968 [Abstract] [Full Text]